Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 1
2010 1
2017 3
2018 2
2020 3
2021 2
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. Stephen B, et al. Among authors: alshawa a. J Immunother Cancer. 2023 Aug;11(8):e007236. doi: 10.1136/jitc-2023-007236. J Immunother Cancer. 2023. PMID: 37604642 Free PMC article.
Adverse Events in Cancer Immunotherapy.
Abdel-Wahab N, Alshawa A, Suarez-Almazor ME. Abdel-Wahab N, et al. Among authors: alshawa a. Adv Exp Med Biol. 2017;995:155-174. doi: 10.1007/978-3-319-53156-4_8. Adv Exp Med Biol. 2017. PMID: 28321817 Review.
The role of Twitter in dental education: A systematic review.
van Schaijik B, Alshawa A, Hamadah O, Alshehri M, Kujan O. van Schaijik B, et al. Among authors: alshawa a. J Dent Educ. 2021 Sep;85(9):1471-1481. doi: 10.1002/jdd.12621. Epub 2021 May 4. J Dent Educ. 2021. PMID: 33948963 Review.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Knisely A, et al. Among authors: alshawa a. Cancer. 2024 Feb 1;130(3):400-409. doi: 10.1002/cncr.35063. Epub 2023 Oct 21. Cancer. 2024. PMID: 37864520 Clinical Trial.
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.
Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Colen RR, et al. Among authors: alshawa a. Invest New Drugs. 2018 Aug;36(4):601-607. doi: 10.1007/s10637-017-0524-2. Epub 2017 Oct 27. Invest New Drugs. 2018. PMID: 29075985 Free PMC article.
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors.
Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing A. Tapia C, et al. Among authors: alshawa a. J Immunother Cancer. 2020 Apr;8(1):e000665. doi: 10.1136/jitc-2020-000665. J Immunother Cancer. 2020. PMID: 32303619 Free PMC article. Clinical Trial.
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Naing A, et al. Among authors: alshawa a. J Immunother Cancer. 2020 Mar;8(1):e000347. doi: 10.1136/jitc-2019-000347. J Immunother Cancer. 2020. PMID: 32188704 Free PMC article. Clinical Trial.
16 results